181 related articles for article (PubMed ID: 34285060)
1. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.
Lak NSM; Voormanns TL; Zappeij-Kannegieter L; van Zogchel LMJ; Fiocco M; van Noesel MM; Merks JHM; van der Schoot CE; Tytgat GAM; Stutterheim J
Clin Cancer Res; 2021 Oct; 27(20):5576-5585. PubMed ID: 34285060
[TBL] [Abstract][Full Text] [Related]
2. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
[TBL] [Abstract][Full Text] [Related]
3. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma.
Krsková L; Mrhalová M; Hilská I; Sumerauer D; Drahokoupilová E; Múdry P; Kodet R
Virchows Arch; 2010 May; 456(5):463-72. PubMed ID: 20405298
[TBL] [Abstract][Full Text] [Related]
4. Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) - RMS2005 study.
Glosli H; Bisogno G; Kelsey A; Chisholm JC; Gaze M; Kolb F; McHugh K; Shipley J; Gallego S; Merks JHM; Smeele LE; Mandeville H; Ferrari A; Minard-Colin V; Corradini N; Jenney M; Zanetti I; De Salvo GL; Orbach D;
Eur J Cancer; 2021 Jul; 151():84-93. PubMed ID: 33971448
[TBL] [Abstract][Full Text] [Related]
5. Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.
Michelagnoli MP; Burchill SA; Cullinane C; Selby PJ; Lewis IJ
Med Pediatr Oncol; 2003 Jan; 40(1):1-8. PubMed ID: 12426678
[TBL] [Abstract][Full Text] [Related]
6. Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma.
Lak NSM; van Zogchel LMJ; Zappeij-Kannegieter L; Javadi A; van Paemel R; Vandeputte C; De Preter K; De Wilde B; Chicard M; Iddir Y; Schleiermacher G; Ruhen O; Shipley J; Fiocco M; Merks JHM; van Noesel MM; van der Schoot CE; Tytgat GAM; Stutterheim J
JCO Precis Oncol; 2023 Jan; 7():e2200113. PubMed ID: 36652664
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
8. Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay.
Gallego S; Llort A; Roma J; Sabado C; Gros L; de Toledo JS
J Cancer Res Clin Oncol; 2006 Jun; 132(6):356-62. PubMed ID: 16435141
[TBL] [Abstract][Full Text] [Related]
9. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
10. Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups.
Gallego S; Chi YY; De Salvo GL; Li M; Merks JHM; Rodeberg DA; van Scheltinga ST; Mascarenhas L; Orbach D; Jenney M; Million L; Minard-Colin V; Wolden S; Zanetti I; Parham DM; Mandeville H; Venkatramani R; Bisogno G; Hawkins DS;
Pediatr Blood Cancer; 2021 Mar; 68(3):e28832. PubMed ID: 33245207
[TBL] [Abstract][Full Text] [Related]
11. Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study.
Terwisscha van Scheltinga SEJ; Wijnen MHWA; Martelli H; Rogers T; Mandeville H; Gaze MN; McHugh K; Corradini N; Orbach D; Jenney M; Kelsey A; Chisholm J; Gallego S; Glosli H; Ferrari A; Zanetti I; De Salvo GL; Minard-Colin V; Bisogno G; van Noesel MM; Merks HHM
Cancer Med; 2020 Oct; 9(20):7580-7589. PubMed ID: 32869534
[TBL] [Abstract][Full Text] [Related]
12. Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram.
De Salvo GL; Del Bianco P; Minard-Colin V; Chisholm J; Jenney M; Guillen G; Devalck C; Van Rijn R; Shipley J; Orbach D; Kelsey A; Rogers T; Guerin F; Scarzello G; Ferrari A; Cesen Mazic M; Merks JHM; Bisogno G;
Cancer; 2024 Feb; ():. PubMed ID: 38400828
[TBL] [Abstract][Full Text] [Related]
13. Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
Sartori F; Alaggio R; Zanazzo G; Garaventa A; Di Cataldo A; Carli M; Rosolen A;
Cancer; 2006 Apr; 106(8):1766-75. PubMed ID: 16544315
[TBL] [Abstract][Full Text] [Related]
14. Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Martin-Giacalone BA; Li H; Scheurer ME; Casey DL; Dugan-Perez S; Marquez-Do DA; Muzny D; Gibbs RA; Barkauskas DA; Hall D; Stewart DR; Schiffman JD; McEvoy MT; Khan J; Malkin D; Linardic CM; Crompton BD; Shern JF; Skapek SX; Venkatramani R; Hawkins DS; Sabo A; Plon SE; Lupo PJ
JAMA Netw Open; 2024 Mar; 7(3):e244170. PubMed ID: 38546643
[TBL] [Abstract][Full Text] [Related]
15. Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study-EpSSG NRSTS 2005.
Brennan B; De Salvo GL; Orbach D; De Paoli A; Kelsey A; Mudry P; Francotte N; Van Noesel M; Bisogno G; Casanova M; Ferrari A
Eur J Cancer; 2016 Jun; 60():69-82. PubMed ID: 27082136
[TBL] [Abstract][Full Text] [Related]
16. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
17. Optimization of rhabdomyosarcoma disseminated disease assessment by flow cytometry.
Almazán-Moga A; Roma J; Molist C; Vidal I; Jubierre L; Soriano A; Segura MF; Llort A; Sánchez de Toledo J; Gallego S
Cytometry A; 2014 Dec; 85(12):1020-9. PubMed ID: 25155056
[TBL] [Abstract][Full Text] [Related]
18. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
[TBL] [Abstract][Full Text] [Related]
19. Extremity Rhabdomyosarcoma-An Integrated Clinicopathologic and Genomic Study to Improve Risk Stratification.
de Traux de Wardin H; Xu B; Dermawan JK; Smith MH; Wolden SL; Antonescu CR; Wexler LH
JCO Precis Oncol; 2023 Jun; 7(1):e2200705. PubMed ID: 37315267
[TBL] [Abstract][Full Text] [Related]
20. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study.
Ferrari A; Chisholm JC; Jenney M; Minard-Colin V; Orbach D; Casanova M; Guillen G; Glosli H; van Rijn RR; Schoot RA; Cameron AL; Rogers T; Alaggio R; Ben-Arush M; Mandeville HC; Devalck C; Defachelles AS; Coppadoro B; Bisogno G; Merks JHM
Lancet Child Adolesc Health; 2022 Aug; 6(8):545-554. PubMed ID: 35690071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
